As of November 6, 2026, Biomarin Pharmaceutical Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 14, 2026, naming 1 appointment. The latest filing names Robert Plenge, appointed (Form 8-K, September 14, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Biomarin Pharmaceutical Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Biomarin Pharmaceutical Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-14. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Biomarin Pharmaceutical Inc files it.
Also on the record for Biomarin Pharmaceutical Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 4, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 10% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.25% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 9.1% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by VIKING GLOBAL INVESTORS LP | 4.3% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by PRIMECAP MANAGEMENT CO/CA/ | 8.24% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by VIKING GLOBAL INVESTORS LP | 6.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Biomarin Pharmaceutical Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Biomarin Pharmaceutical Inc and the records around it.
Biomarin Pharmaceutical Inc elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- PRIMECAP MANAGEMENT CO/CA/ also filed stake reports on 24 other companies: Xencor Inc (Nov 2026), GRAIL, Inc. (Nov 2026), MARKETAXESS HOLDINGS INC (Nov 2026)
- VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: City Therapeutics, Inc. (Oct 2026), MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
Watch Biomarin Pharmaceutical Inc
Get an email when Biomarin Pharmaceutical Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Biomarin Pharmaceutical Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Biomarin Pharmaceutical Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Biomarin Pharmaceutical Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-14 | In | 2026-09-10 | 8-K, 2026-09-14 |
New leaders reset buying decisions — get the Full Report on Biomarin Pharmaceutical Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Biomarin Pharmaceutical Inc, with the record behind each one.
Find candidates like senior executive at Biomarin Pharmaceutical IncEvery change, in the filing's words
Appointed: Robert Plenge, effective 2026-09-10
On September 10, 2026, the Board of Directors (the Board) of BioMarin Pharmaceutical Inc. (the Company) increased the size of the Board from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., to the Board, to be effective September 10, 2026 (the Appointment Date).
- Dr. Plenge has also been appointed to the Science and Technology Committee of the Board.
- As an independent non-employee director, Dr. Plenge will be entitled to receive the standard director fees paid to the Company's non-employee directors and retainer fees paid to members of the Board committees on which he will sit, as described under the heading "Director Compensation" in the Company's definitive proxy statement on Schedule 14A (the Proxy Statement), filed with the Securities and Exchange Commission (the SEC) on April 21, 2026.
- In connection with his appointment to the Board, on the Appointment Date, Dr. Plenge was granted a number of restricted stock units (the RSU Grant) valued at $400,000 pursuant to the Company's 2017 Equity Incentive Plan, as amended, which is based on a pro rata share of the 2026 annual award for non-employee directors as described in the Proxy Statement and consistent with Company policy.
- The shares of common stock subject to the RSU Grant will vest on the date immediately prior to the date of the Company's next regular annual meeting of stockholders, the same vesting date for the 2026 annual award for all other non-employee directors.
Tools for this story
Each opens in a new tab, filled in for Biomarin Pharmaceutical Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.